Biovally in Kunming became the first company from Yunnan to be traded on the newly-established Beijing Stock Exchange.
Established in 1999, it is a high-tech pharmaceutical company integrating research, development, production and sales of breviscapine, a type of medicine. Over the last two decades, the company has been committed to the research and development of this medicine.
It has a national-level enterprise technology center, post-doctoral research workstation and other research and development platforms, and has won several national honors.
At present, the company has established a breviscapine industrial chain platform integrating research, processing, production, and marketing, and is in the leading position in the industry in terms of production, sales, and varieties.
The Beijing Stock Exchange started trading on Monday. It marks a new chapter in the reform and development of China's capital market, which is trying to better serve its innovative small and medium-sized enterprises. A total of 81 SMEs are listed on the new bourse so far.
